<DOC>
	<DOCNO>NCT02274415</DOCNO>
	<brief_summary>Streptococcus pneumoniae major cause bacterial infection patient sickle cell disease . The 23-valent pneumococcal polysaccharide vaccine ( PSV ) suppose poorly immunogenic patient . We want evaluate whether prime 13-valent pneumococcal conjugate vaccine ( PCV ) , able induce immunologic memory , would improve immune response SP polysaccharide ( SPP ) . Primary objective : To evaluate compare specific antibody response prime-boost vaccine strategy combine PCV prime W0 follow administration PSV boost W4 , administration PSV alone W4 patient sickle cell disease . Secondary objective : Evaluation comparison specific antibody response thirteen pneumococcal serotypes share PCV PSV vaccine , 4 week single PSV vaccination patient Group 1 4 week boost PSV vaccination patient group 2 . Evaluation duration specific antibody response W24 96 . Evaluation T CD4 lymphocyte response CRM 197 protein . Safety vaccine . Study Design : Randomised , monocentric , control phase II study immunological efficacy prime boost strategy combine sequential administration PCV PSV , compare administration PSV alone . 180 adults patient sickle cell disease include . The primary endpoint : proportion responder W8 least 10 thirteen serotypes . Secondary endpoint : Proportion responder W8 accord 4 category responder : 5-7 ; 3-4 ; 2-1 0 . Evaluation pneumococcal opsonophagocytic activity ( OPA ) baseline W8 serotype , define proportion patient OPA &gt; 1:8 geometric mean specific antibody titer proportion patient experience increase specific antibody level 1 g/ml . Evaluation prim effect PCV vaccine group 1 . Duration specific antibody responses week 24 W96 . CD4 T lymphocyte response CRM 197 protein ( proliferative cytokine production ) week 0 , 8 12 . Safety vaccines frequency Streptococcus pneumoniae infection . Statistical Considerations : With sample size 180 patient , randomization ration 1:1 , study power least 90 % show difference 25 % category group receive PCV PSV v group receive PSV alone ( two-sided type I error = 5 % ) . The primary comparison group perform use Chi2 test independent group Fisher exact test appropriate .</brief_summary>
	<brief_title>Immunogenicity Study Anti-pneumococcal Vaccination Strategy Patients With Sickle Cells Disease</brief_title>
	<detailed_description />
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Age ≥ 18 year Adult patient sickle cell anemia ( SS homozygous , SC heterozygous compound Sbetathal heterozygous ) Heterozygous sickle cell anemia Active infection Hypersensitivity know suspect Prevenar 13® Pneumo 23® excipients include formulation administration system Coagulation abnormality indicate intramuscular injection ( Platelets &lt; 50 000 TP &lt; 50 % ) Current chemotherapy radiotherapy , except use Siklos®/Hydrea® context sickle cell anemia Vaccination whatever last 2 month inclusion , except influenza vaccination ( within 30 day ) Vaccination whatever , provide first 2 month participation research , except influenza vaccination ( first month participation research ) History pneumococcal vaccination Pneumo 23® previous 3 year History pneumococcal vaccination Pneumo 23® Endstage renal failure ( dialyzed patient , clearance &lt; 10ml/mn ) HIV infection baseline Pregnancy breastfeeding ( A dosage betaHCG conduct woman childbearing age ) Contraception first 8 week test woman childbearing age Participation clinical research protocol use drug vaccine previous month No medical assurance Adults tutelage</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Streptococcus pneumoniae</keyword>
	<keyword>Sickle cell disease</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Antibody response</keyword>
</DOC>